Tranexamic Acid for Post‑partum Hemorrhage: Dosing, Timing, and Contra‑indications

1. Evidence Gap for First‑Trimester Bleeding

• Current guidelines and research address only post‑partum hemorrhage; there is no evidence supporting the use of tranexamic acid for first‑trimester bleeding. 1, 2

2. Dosing Regimen (Full‑term Post‑partum Hemorrhage)

• Initial dose: 1 g tranexamic acid administered intravenously at 1 mL/min over 10 minutes. 1, 2
• Second dose: An additional 1 g IV dose is recommended if bleeding persists after 30 minutes or if bleeding recurs within 24 hours of the first dose. 1, 2

3. Timing and Efficacy

• The drug must be given within 3 hours of delivery to confer benefit; administration after this window provides no advantage and may be harmful. 1, 2
• Effectiveness declines by ~10 % for every 15‑minute delay in administration, emphasizing the need for rapid treatment. 1, 2
• Early administration (as soon as postpartum hemorrhage is diagnosed) increases survival benefit. 1

4. Indications and Definition of Post‑partum Hemorrhage (PPH)

• Tranexamic acid should be administered in all cases of PPH regardless of cause (uterine atony, genital‑tract trauma, retained tissue, etc.). 1, 2
• Clinically diagnosed PPH is defined as:
  
  • Estimated blood loss > 500 mL after vaginal delivery or > 1000 mL after cesarean delivery, or any loss that compromises hemodynamic stability. 1, 2

5. Contra‑indications and Safety Considerations

• Absolute contra‑indications: documented thrombo‑embolic event during pregnancy (e.g., deep‑vein thrombosis, pulmonary embolism) or active intravascular clotting. 1, 2
• When used appropriately for PPH, tranexamic acid does not increase maternal thrombotic events. 1
• The principal safety risk is accidental intrathecal injection due to medication‑mix‑up; strict medication‑safety protocols are required. 1

6. Administration Route

• Intravenous administration only is recommended; oral or intramuscular routes are not endorsed pending further research. 1, 2

7. Clinical Decision Algorithm (Key Steps)

• Step 1 – Diagnose PPH: blood loss > 500 mL (vaginal) or > 1000 mL (cesarean) or hemodynamic compromise. 1, 2
• Step 2 – Check contra‑indications: ensure no history of pregnancy‑related thrombo‑embolism or active clotting. 1, 2
• Step 3 – Assess timing: if < 3 hours since birth, proceed; if ≥ 3 hours, do not give tranexamic acid. 1, 2
• Step 4 – Administer first dose: 1 g IV over 10 minutes immediately. 1, 2
• Step 5 – Re‑evaluate at 30 minutes: give second 1 g IV dose if bleeding continues. 1, 2
• Step 6 – Monitor for 24 hours: if bleeding restarts and a second dose has not yet been given, administer the additional 1 g IV dose. 1, 2

8. Common Pitfalls to Avoid

• Do not delay tranexamic acid while awaiting laboratory results or other interventions; give it promptly alongside uterotonic agents and uterine massage. 1
• Do not administer tranexamic acid beyond the 3‑hour post‑delivery window, as it offers no benefit and may cause harm. 1, 2
• Do not withhold the drug based on presumed bleeding etiology; it is indicated for all PPH causes. 1, 2
• Do not use tranexamic acid prophylactically in women without active bleeding during vaginal or cesarean delivery. 1

Use of Tranexamic Acid During Pregnancy

Indications for TXA During Pregnancy

• The American College of Obstetricians and Gynecologists recommends TXA for the treatment of postpartum hemorrhage (PPH) and should be administered as soon as possible, within 3 hours of birth, for maximum effectiveness 3, 4
• In women with congenital fibrinogen disorders who have a bleeding phenotype, the International Society on Thrombosis and Haemostasis suggests TXA for prophylaxis at the time of delivery 5
• TXA may be considered for prevention of secondary PPH and management of prolonged or heavy lochia, depending on thrombotic risk, according to the Journal of Thrombosis and Haemostasis 5
• For pregnancy loss management in women with afibrinogenemia and severe hypofibrinogenemia, TXA is recommended for 3 days along with fibrinogen replacement targeting levels ≥1.5 g/L, as per the Journal of Thrombosis and Haemostasis 5

Dosing and Administration

• For PPH treatment, the recommended dose is 1g IV administered over 10 minutes, with a possible second dose if bleeding continues after 30 minutes or restarts within 24 hours, as recommended by The Lancet Global Health 4
• Efficacy decreases by approximately 10% for every 15-minute delay in administration, with no benefit seen after 3 hours post-birth, according to The Lancet Global Health 4

Safety Considerations

• TXA should be avoided in women with clear contraindications to antifibrinolytic therapy, such as known thromboembolic events during pregnancy, as stated by The Lancet Global Health 3

Clinical Decision Algorithm

• Check for contraindications: History of thromboembolic events or other clear contraindications to antifibrinolytic therapy, as recommended by The Lancet Global Health 3
• Consider timing: For PPH treatment, administer within 3 hours of birth, preferably as soon as possible, according to The Lancet Global Health 4
• Monitor for adverse effects, particularly signs of thromboembolism, as recommended by The Lancet Global Health 4

Tranexamic Acid Administration Route

Introduction to Tranexamic Acid Administration

• Tranexamic acid (Tranexa) injection is administered intravenously (IV), not intramuscularly (IM), as recommended by the World Health Organization (WHO) 6, 7

Contraindications and Safety Considerations

• Tranexamic acid is contraindicated in patients with active intravascular clotting or history of thromboembolic events during pregnancy, according to the WHO guidelines 7

Research and Guidelines

• The WHO guidelines specifically state that recommendations apply to intravenous administration only, as benefits and potential harms of other routes remain a research priority 6, 7